Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

Dovato approval key for Glaxo in HIV treatment

First single tablet for treatment-naïve patients

Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase

We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...

Inizio

Infographic: Rheumatoid arthritis (RA)

An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...

Inizio

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Inizio

Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market

Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST

Inizio

- PMLiVE

Merck KGaA exec takes top job at UK biotech Kymab

UK biotech veteran returns to head antibody specialist

- PMLiVE

UniQure gets speedy US review for Huntington’s gene therapy

Pioneer gaining momentum again

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

scientific services porterhouse medical

Rewarding excellence within Porterhouse Medical’s scientific services team.

At Porterhouse Medical, we are very proud of our hard-working teams and are always delighted to recognise career progression within the agency. With this in mind, we are thrilled to...

Porterhouse Medical Group

Roche Basel Switzerland

Roche says ‘discovery proteomics’ is heading for clinical trials

Tech has potential to identify novel biomarkers

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links